{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:32:13Z","timestamp":1791595933156,"version":"4.3.4"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00277-023-05294-3","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T13:01:52Z","timestamp":1685797312000},"page":"1657-1667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Sickle cell disease and acute leukemia: one case report and an extensive review"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6785-7709","authenticated-orcid":false,"given":"Giovanna","family":"Cannas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne","family":"Poutrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00ebl","family":"Heiblig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Labussi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Virginie","family":"Larcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Hot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,3]]},"reference":[{"key":"5294_CR1","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJMra1510865","volume":"376","author":"FB Piel","year":"2017","unstructured":"Piel FB, Steinberg MH, Rees DC (2017) Sickle cell disease. N Engl J Med 376:1561\u20131573","journal-title":"N Engl J Med"},{"key":"5294_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1001\/archinte.1910.00050330050003","volume":"6","author":"JD Herrick","year":"1910","unstructured":"Herrick JD (1910) Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med 6:517\u2013521","journal-title":"Arch Intern Med"},{"key":"5294_CR3","doi-asserted-by":"publisher","first-page":"920","DOI":"10.7326\/0003-4819-39-4-920","volume":"39","author":"AG Goldin","year":"1953","unstructured":"Goldin AG, Kelty KC, Beard MF (1953) Sickle cell anemia terminating in acute myeloblastic leukemia. Ann Intern Med 39:920\u2013928","journal-title":"Ann Intern Med"},{"key":"5294_CR4","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405","journal-title":"Blood"},{"key":"5294_CR5","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1182\/blood-2017-05-783233","volume":"130","author":"A Brunson","year":"2017","unstructured":"Brunson A, Keegan THM, Bang H et al (2017) Increased risk of leukemia among sickle cell disease patients in California. Blood 130:1597\u20131599","journal-title":"Blood"},{"key":"5294_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/0141076816651037","volume":"109","author":"OO Seminog","year":"2016","unstructured":"Seminog OO, Ogunlaja OI, Yeates D et al (2016) Risk of individual malignant neoplasms in patients with sickle cell disease: English National Record Linkage Study. J R Soc Med 109:303\u2013309","journal-title":"J R Soc Med"},{"key":"5294_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/000992287201100313","volume":"183","author":"RE Jackson","year":"1972","unstructured":"Jackson RE, Short BJ (1972) Frequency and prognosis of coexisting sickle cell disease and acute leukemia in children. Clin Pediatr 183:183\u2013185","journal-title":"Clin Pediatr"},{"key":"5294_CR8","first-page":"453","volume":"16","author":"GC Samal","year":"1979","unstructured":"Samal GC (1979) Sickle cell anemia with acute myeloid leukemia \u2013 (a case report). Indian Pediatr 16:453\u2013454","journal-title":"Indian Pediatr"},{"key":"5294_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/0002-9343(82)90189-9","volume":"73","author":"C Conference","year":"1982","unstructured":"Conference C (1982) Left elbow pain and death in a young woman with sickle-cell anemia. Am J Med 73:268\u2013282","journal-title":"Am J Med"},{"key":"5294_CR10","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1056\/NEJM198409203111207","volume":"311","author":"FL Johnson","year":"1984","unstructured":"Johnson FL, Look AT, Gockerman J et al (1984) Bone marrow transplantation in a patient with sickle-cell anemia. N Engl J Med 311:780\u2013783","journal-title":"N Engl J Med"},{"key":"5294_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0165-4608(86)90007-5","volume":"21","author":"SH Bigner","year":"1986","unstructured":"Bigner SH, Friedman HS, Kinney TR et al (1986) 9p\u2212 in a girl with acute lymphocytic leukemia and sickle cell disease. Cancer Genet Cytogenet 21:267\u2013269","journal-title":"Cancer Genet Cytogenet"},{"key":"5294_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ajh.2830210212","volume":"21","author":"RB Stricker","year":"1986","unstructured":"Stricker RB, Linker CA, Crowley TJ, Embury SH (1986) Hematology malignancy in sickle cell disease: report of four cases and review of the literature. Am J Hematol 21:223\u2013230","journal-title":"Am J Hematol"},{"key":"5294_CR13","first-page":"158","volume":"34","author":"OS Njoku","year":"1988","unstructured":"Njoku OS, Johnson SB, Kulkarni AG, Mba EC (1988) Acute lymphoblastic leukaemia in a Nigerian adult with sickle cell anaemia. Centr Afr J Med 34:158\u2013160","journal-title":"Centr Afr J Med"},{"key":"5294_CR14","first-page":"744","volume":"123","author":"EA Sotomayer","year":"1999","unstructured":"Sotomayer EA, Glasser L (1999) Acute lymphoblastic leukemia in sickle cell disease. Arch Pathol Lab Med 123:744\u2013745","journal-title":"Arch Pathol Lab Med"},{"key":"5294_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/adc.81.5.437","volume":"81","author":"M De Montalembert","year":"1999","unstructured":"De Montalembert M, B\u00e9gu\u00e9 P, Bernaudin F et al (1999) Preliminary report of a toxicity study of hydroxyurea in sickle cell disease: French Study Group on Sickle Cell Disease. Arch Dis Child 81:437\u2013439","journal-title":"Arch Dis Child"},{"issue":"suppl.1","key":"5294_CR16","first-page":"415a","volume":"94","author":"A Rauch","year":"1999","unstructured":"Rauch A, Borromeo M, Ghafoor A et al (1999) Leukemogenesis of hydroxyurea in the treatment of sickle cell anemia. Blood 94(suppl.1):415a","journal-title":"Blood"},{"key":"5294_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.7326\/0003-4819-133-11-200012050-00029","volume":"133","author":"S Wilson","year":"2000","unstructured":"Wilson S (2000) Acute leukemia in a patient with sickle cell anemia treated with hydroxyurea. Ann Intern Med 133:925\u2013926","journal-title":"Ann Intern Med"},{"key":"5294_CR18","first-page":"1411","volume":"23","author":"AH Al-Jam\u2019a","year":"2002","unstructured":"Al-Jam\u2019a AH, Al-Dabbous IA, Al-Khatti AA, Esan FG (2002) Are we underestimating the leukemogenic risk of hydroxyurea. Saudi Med J 23:1411\u20131413","journal-title":"Saudi Med J"},{"key":"5294_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/ajh.10427","volume":"74","author":"WH Schultz","year":"2003","unstructured":"Schultz WH, Ware RE (2003) Malignancy in patients with sickle cell disease. Am J Hematol 74:249\u2013253","journal-title":"Am J Hematol"},{"key":"5294_CR20","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1046\/j.1365-2141.2003.04614.x","volume":"123","author":"A Ferster","year":"2003","unstructured":"Ferster A, Sariban E, Meuleman N (2003) Malignancies in sickle cell disease patients treated with hydroxyurea. Br J Haematol 123:368\u2013369","journal-title":"Br J Haematol"},{"key":"5294_CR21","doi-asserted-by":"publisher","first-page":"722","DOI":"10.7326\/0003-4819-155-10-201111150-00024","volume":"155","author":"JG Taylor","year":"2011","unstructured":"Taylor JG, Darari DS, Maric I et al (2011) Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia. Ann Intern Med 155:722\u2013724","journal-title":"Ann Intern Med"},{"key":"5294_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4137\/CMO.S8810","volume":"6","author":"W Baz","year":"2012","unstructured":"Baz W, Najfeld V, Yotsuya M et al (2012) Development of myelodysplastic syndrome and acute myeloid leukemia 15 years after hydroxyurea use in a patient with sickle cell anemia. Clin Med Insights Oncol 6:149\u2013152","journal-title":"Clin Med Insights Oncol"},{"key":"5294_CR23","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/ajh.23768","volume":"89","author":"S Zemenides","year":"2014","unstructured":"Zemenides S, Erblich T, Luqmani A, Bain BJ (2014) Peripheral blood features of acute myeloid leukemia with myelodysplasia-related changes developing in a patient with sickle cell anemia. Am J Hematol 89:1010","journal-title":"Am J Hematol"},{"key":"5294_CR24","doi-asserted-by":"publisher","first-page":"E131","DOI":"10.1002\/ajh.24010","volume":"90","author":"C Aumont","year":"2015","unstructured":"Aumont C, Driss F, Lazure T et al (2015) Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia. Am J Hematol 90:E131\u2013E132","journal-title":"Am J Hematol"},{"key":"5294_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.22159\/ajpcr.2018.v11i3.22790","volume":"11","author":"S Chauhan","year":"2018","unstructured":"Chauhan S, Swain SK, Sahu MC (2018) Incidence of hematological malignancies in sickle cell patients from an Indian tertiary care teaching hospital. Asian J Pharm Clin Res 11:205\u2013209","journal-title":"Asian J Pharm Clin Res"},{"key":"5294_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/10428194.2017.1324158","volume":"59","author":"M Janakiram","year":"2018","unstructured":"Janakiram M, Verma A, Wang Y et al (2018) Accerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease. Leuk Lymphoma 59:241\u2013244","journal-title":"Leuk Lymphoma"},{"key":"5294_CR27","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41379-019-0325-6","volume":"32","author":"Y Li","year":"2019","unstructured":"Li Y, Maule J, Neff JL et al (2019) Myeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature. Modern Pathol 32:1712\u20131726","journal-title":"Modern Pathol"},{"key":"5294_CR28","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1016\/S2352-3026(19)30154-1","volume":"6","author":"M Eapen","year":"2019","unstructured":"Eapen M, Brazauskas R, Walters MC et al (2019) Impact of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective, cohort study. Lancet Haematol 6:e585\u2013e596","journal-title":"Lancet Haematol"},{"key":"5294_CR29","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1080\/15384047.2019.1647055","volume":"20","author":"S Regan","year":"2019","unstructured":"Regan S, Yang X, Finnberg NK et al (2019) Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient. Cancer Biol Ther 20:1389\u20131397","journal-title":"Cancer Biol Ther"},{"key":"5294_CR30","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.4314\/ahs.v20i3.36","volume":"20","author":"OW Aworanti","year":"2020","unstructured":"Aworanti OW, Fasola FA, Kotila TR et al (2020) Acute leukemia in sickle cell disease patients in a tertiary health facility in Nigeria: a case series. Afri Health Sci 20:1304\u20131312","journal-title":"Afri Health Sci"},{"key":"5294_CR31","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1159\/000508361","volume":"13","author":"DK Yadav","year":"2020","unstructured":"Yadav DK, Paul T, Alhamar M et al (2020) Pure erythroid leukemia in a sickle cell patient treated with hydroxyurea. Case Rep Oncol 13:857\u2013862","journal-title":"Case Rep Oncol"},{"key":"5294_CR32","first-page":"1185","volume":"135","author":"JY Ghannam","year":"2020","unstructured":"Ghannam JY, Xu X, Maric I et al (2020) Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation. Blood 135:1185\u20131188","journal-title":"Blood"},{"key":"5294_CR33","doi-asserted-by":"publisher","first-page":"e13641","DOI":"10.1111\/petr.13641","volume":"24","author":"D Chellapandian","year":"2020","unstructured":"Chellapandian D, Nicholson CL (2020) Haploidentical bone marrow transplantation in a patient with sickle cell disease and acute myeloid leukemia. Pediatr Transplant 24:e13641","journal-title":"Pediatr Transplant"},{"key":"5294_CR34","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1182\/bloodadvances.2019001330","volume":"4","author":"MM Hsieh","year":"2020","unstructured":"Hsieh MM, Bonner M, Pierciey FJ et al (2020) Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Adv 4:2058\u20132063","journal-title":"Blood Adv"},{"key":"5294_CR35","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1186\/s13256-021-03060-5","volume":"15","author":"IO Ahmed","year":"2021","unstructured":"Ahmed IO, Ochogwu LO, Owojuyigbe TO et al (2021) Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with e1a3 BCR-ABL1 transcript in a Nigerian with sickle cell anemia: a case report. J Med Case Reports 15:504","journal-title":"J Med Case Reports"},{"key":"5294_CR36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2109167","volume":"386","author":"S Goyal","year":"2022","unstructured":"Goyal S, Tisdale J, Schmidt M et al (2022) Acute myeloid leukemia after gene therapy for sickle cell disease. N Engl J Med 386:138\u2013147","journal-title":"N Engl J Med"},{"key":"5294_CR37","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.3390\/biomedicines10123201","volume":"10","author":"P Flevari","year":"2022","unstructured":"Flevari P, Voskaridou E, Galacteros F et al (2022) Case report of myelodysplastic syndrome in a sickle-cell disease patient treated with hydroxyurea and literature review. Biomedicines 10:3201","journal-title":"Biomedicines"},{"key":"5294_CR38","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1080\/1042819022386833","volume":"43","author":"S Paydas","year":"2002","unstructured":"Paydas S (2002) Sickle cell anemia and hematological neoplasias. Leuk Lymphoma 43:1431\u20131434","journal-title":"Leuk Lymphoma"},{"key":"5294_CR39","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/(SICI)1096-8652(199707)55:4<188::AID-AJH4>3.0.CO;2-O","volume":"55","author":"FW Dawkins","year":"1997","unstructured":"Dawkins FW, Kim KS, Squires RS et al (1997) Cancer incidence rate and mortality rate in sickle cell disease patients at Howard University Hospital: 1986\u20131995. Am J Hematol 55:188\u2013192","journal-title":"Am J Hematol"},{"key":"5294_CR40","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/pr.2013.227","volume":"75","author":"NS Green","year":"2014","unstructured":"Green NS, Barral S (2014) Emerging science of hydroxyurea therapy for pediatric sickle cell disease. Pediatr Res 75:196\u2013204","journal-title":"Pediatr Res"},{"key":"5294_CR41","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","volume":"289","author":"MH Steinberg","year":"2003","unstructured":"Steinberg MH, Barton F, Castro O et al (2003) Effect of hydroxyurea on mortalityand morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289:1645\u20131651","journal-title":"JAMA"},{"key":"5294_CR42","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","volume":"332","author":"S Charache","year":"1995","unstructured":"Charache S, Terrin ML, Moore RD et al (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 332:1317\u20131322","journal-title":"N Engl J Med"},{"key":"5294_CR43","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1182\/blood.V88.6.1960.bloodjournal8861960","volume":"88","author":"A Ferster","year":"1996","unstructured":"Ferster A, Vermylen C, Cornu G et al (1996) Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 88:1960\u20131964","journal-title":"Blood"},{"key":"5294_CR44","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","volume":"377","author":"WC Wang","year":"2011","unstructured":"Wang WC, Ware RE, Miller ST et al (2011) Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 377:1663\u20131672","journal-title":"Lancet"},{"key":"5294_CR45","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.mrgentox.2012.08.003","volume":"749","author":"LB Da Silva Rocha","year":"2012","unstructured":"Da Silva Rocha LB, Dias Elias DB, Barbosa MC et al (2012) DNA damage in leukocytes of sickle cell anemia patients is associated with hydroxyurea therapy and with HBB*S haplotype. Mutat Res 749:48\u201352","journal-title":"Mutat Res"},{"key":"5294_CR46","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/em.22260","volume":"60","author":"PA Maia Filho","year":"2019","unstructured":"Maia Filho PA, Pereira JF, Almeida Filho TPD et al (2019) Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity. Environ Mol Mutagen 60:302\u2013304","journal-title":"Environ Mol Mutagen"},{"key":"5294_CR47","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","volume":"29","author":"JJ Kiladjian","year":"2011","unstructured":"Kiladjian JJ, Chevret S, Dosquet C et al (2011) Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 29:3907\u20133913","journal-title":"J Clin Oncol"},{"key":"5294_CR48","doi-asserted-by":"publisher","first-page":"939","DOI":"10.7326\/0003-4819-148-12-200806170-00221","volume":"148","author":"S Lanzkron","year":"2008","unstructured":"Lanzkron S, Strouse JJ, Wilson R et al (2008) Systematic review: hydroxyurea for the treatment of adults with sickle cell diseases. Ann Intern Med 148:939\u2013955","journal-title":"Ann Intern Med"},{"key":"5294_CR49","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ajh.21699","volume":"85","author":"MH Steinberg","year":"2010","unstructured":"Steinberg MH, McCarthy WF, Castro O et al (2010) The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol 85:403\u2013408","journal-title":"Am J Hematol"},{"key":"5294_CR50","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1182\/blood-2009-05-221333","volume":"115","author":"E Voskaridou","year":"2010","unstructured":"Voskaridou E, Christoulas D, Bilalis A et al (2010) The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 115:2354\u20132363","journal-title":"Blood"},{"key":"5294_CR51","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/bjh.13093","volume":"167","author":"O Castro","year":"2014","unstructured":"Castro O, Nouraie M, Oneal P (2014) Hydroxycarbamide treatment in sickle cell disease: estimates of possible leukaemia risk and of hospitalization survival benefit. Br J Haematol 167:687\u2013691","journal-title":"Br J Haematol"},{"key":"5294_CR52","first-page":"1550","volume":"94","author":"TR Kinney","year":"1999","unstructured":"Kinney TR, Helms RW, O\u2019Branski EE et al (1999) Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I\/II trial. Blood 94:1550\u20131554","journal-title":"Blood"},{"key":"5294_CR53","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1182\/blood.V97.11.3628","volume":"97","author":"A Ferster","year":"2001","unstructured":"Ferster A, Tahriri P, Vermylen C et al (2001) Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 97:3628\u20133632","journal-title":"Blood"},{"key":"5294_CR54","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.mrgentox.2010.03.001","volume":"698","author":"JM Flanagan","year":"2010","unstructured":"Flanagan JM, Howard TA, Mortier N et al (2010) Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res 698:38\u201342","journal-title":"Mutat Res"},{"key":"5294_CR55","doi-asserted-by":"publisher","first-page":"e27022","DOI":"10.1002\/pbc.27022","volume":"65","author":"A Rodriguez","year":"2018","unstructured":"Rodriguez A, Duez P, Dedeken L et al (2018) Hydroxyurea (hydroxycarbamine) genotoxicity in pediatric patients with sickle cell disease. Pediatr Blood Cancer 65:e27022","journal-title":"Pediatr Blood Cancer"},{"key":"5294_CR56","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.17323","volume":"194","author":"RE Ware","year":"2021","unstructured":"Ware RE, Dertinger SD (2021) Absence of hydroxyurea-induced mutational effects supports higher utilization for the treatment of sickle cell anaemia. Br J Haematol 194:252\u2013266","journal-title":"Br J Haematol"},{"key":"5294_CR57","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1182\/blood.V95.11.3589","volume":"95","author":"V Hanft","year":"2000","unstructured":"Hanft V, Fruchtman S, Pickens C et al (2000) Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood 95:3589\u20133593","journal-title":"Blood"},{"key":"5294_CR58","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/ajh.26286","volume":"96","author":"M De Montelembert","year":"2021","unstructured":"De Montelembert M, Voskaridou E, Oevermann L et al (2021) Real-life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study. Am J Hematol 96:1223\u20131231","journal-title":"Am J Hematol"},{"key":"5294_CR59","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0268-960X(03)00006-7","volume":"17","author":"C Vermylen","year":"2003","unstructured":"Vermylen C (2003) Hematopoietic stem cell transplantation in sickle cell disease. Blood Rev 17:163\u2013166","journal-title":"Blood Rev"},{"key":"5294_CR60","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","volume":"129","author":"E Gluckman","year":"2017","unstructured":"Gluckman E, Cappelli B, Bernaudin F et al (2017) Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood 129:1548\u20131556","journal-title":"Blood"},{"key":"5294_CR61","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood-2002-07-2090","volume":"101","author":"F Locatelli","year":"2003","unstructured":"Locatelli F, Rocha V, Reed W et al (2003) Related umbilical cord blood transplant in patients with thalassemia and sickle cell disease. Blood 101:2137\u20132143","journal-title":"Blood"},{"key":"5294_CR62","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.bbmt.2012.01.019","volume":"18","author":"NR Kamani","year":"2012","unstructured":"Kamani NR, Walters MC, Carter S et al (2012) Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 18:1265\u20131272","journal-title":"Biol Blood Marrow Transplant"},{"key":"5294_CR63","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.bbmt.2017.05.027","volume":"23","author":"A Abraham","year":"2017","unstructured":"Abraham A, Cluster A, Jacobsohn D et al (2017) Unrelated umbilical cord blood transplantation for sickle cell disease following reduced-intensity conditioning: results of a phase I trial. Biol Blood Marrow Transplant 23:1587\u20131592","journal-title":"Biol Blood Marrow Transplant"},{"key":"5294_CR64","doi-asserted-by":"publisher","first-page":"1004.e1","DOI":"10.1016\/j.jtct.2021.09.009","volume":"27","author":"M Aydin","year":"2021","unstructured":"Aydin M, Dovern E, Leeflang MMG et al (2021) Haploidentical allogeneic stem cell transplantation in sickle cell disease: a systematic review and meta-analysis. Transplant Cell Ther 27:1004.e1-1004.e8","journal-title":"Transplant Cell Ther"},{"key":"5294_CR65","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1182\/blood.2021011488","volume":"138","author":"RJ Jones","year":"2021","unstructured":"Jones RJ, DeBaun MR (2021) Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. Blood 138:942\u2013947","journal-title":"Blood"},{"key":"5294_CR66","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2117175","volume":"386","author":"J Kanter","year":"2022","unstructured":"Kanter J, Walters MC, Krishnamurti L et al (2022) Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N Engl J Med 386:617\u2013628","journal-title":"N Engl J Med"},{"key":"5294_CR67","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1200\/JCO.2001.19.5.1405","volume":"19","author":"DH Christiansen","year":"2001","unstructured":"Christiansen DH, Andersen MK, Pedersen-Bjergaard J (2001) Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 19:1405\u20131413","journal-title":"J Clin Oncol"},{"key":"5294_CR68","doi-asserted-by":"crossref","unstructured":"Ribeil JA (2022) Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms? 97:4\u20136","DOI":"10.1002\/ajh.26371"},{"key":"5294_CR69","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ajh.26798","volume":"98","author":"GL Forni","year":"2023","unstructured":"Forni GL, Gianesin B, Musallam KM et al (2023) Overall and complication-free survival in a large cohort of patients with \u03b2-thalassemia major followed over 50 years. Am J Hematol 98:381\u2013387","journal-title":"Am J Hematol"},{"key":"5294_CR70","doi-asserted-by":"publisher","first-page":"8129","DOI":"10.3390\/ijms23158129","volume":"23","author":"J Tomasik","year":"2022","unstructured":"Tomasik J, Basak GW (2022) Inflammasomes \u2013 New contributors to blood diseases. Int J Mol Sci 23:8129","journal-title":"Int J Mol Sci"},{"key":"5294_CR71","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10238-008-0153-3","volume":"8","author":"PM Alves","year":"2008","unstructured":"Alves PM, Martins PRJ, Dias FDL et al (2008) Sensitivity to cisplatin-induced mutations and elevated chromosomal aberrations in lymphocytes from sickle cell disease patients. Clin Exp Med 8:31\u201335","journal-title":"Clin Exp Med"},{"key":"5294_CR72","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrclinonc.2015.105","volume":"12","author":"SM Crusz","year":"2015","unstructured":"Crusz SM, Balkwill FR (2015) Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol 12:584\u2013596","journal-title":"Nat Rev Clin Oncol"},{"key":"5294_CR73","doi-asserted-by":"publisher","first-page":"100744","DOI":"10.1016\/j.blre.2020.100744","volume":"46","author":"MT Nawas","year":"2021","unstructured":"Nawas MT, Schetelig J, Damm F et al (2021) The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation. Blood Rev 46:100744","journal-title":"Blood Rev"},{"key":"5294_CR74","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","volume":"518","author":"TN Wong","year":"2015","unstructured":"Wong TN, Ramsingh G, Young AL et al (2015) Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518:552\u2013555","journal-title":"Nature"},{"key":"5294_CR75","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/ajcn\/65.1.46","volume":"65","author":"YI Kim","year":"1997","unstructured":"Kim YI, Pogribny IP, Basnakian AG et al (1997) Folate deficiency in rats induces DNA strand breaks and hypomethylation within the p53 tumor suppressor gene. Am J Clin Nutr 65:46\u201352","journal-title":"Am J Clin Nutr"},{"key":"5294_CR76","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1126\/science.1905840","volume":"253","author":"M Hollstein","year":"1991","unstructured":"Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) P53 mutations in human cancers. Science 253:49\u201353","journal-title":"Science"},{"key":"5294_CR77","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.3390\/jcm11113160","volume":"11","author":"LP Gondek","year":"2022","unstructured":"Gondek LP, Sheedan VA, Fitzhugh CD (2022) Clonal hematopoiesis and the risk of hematologic malignancies after curative therapies for sickle cell disease. J Clin Med 11:3160","journal-title":"J Clin Med"},{"key":"5294_CR78","doi-asserted-by":"publisher","first-page":"E2159","DOI":"10.3390\/cells9102159","volume":"9","author":"SS Tolu","year":"2020","unstructured":"Tolu SS, Wang K, Yan Z et al (2020) Characterization of hematopoiesis in sickle cell disease by prospective isolation of stem and progenitor cells. Cells 9:E2159","journal-title":"Cells"},{"key":"5294_CR79","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1172\/JCI10726","volume":"106","author":"OS Platt","year":"2000","unstructured":"Platt OS (2000) Sickle cell anemia as an inflammatory disease. J Clin Invest 106:337\u2013338","journal-title":"J Clin Invest"},{"key":"5294_CR80","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/7651_2019_216","volume":"2045","author":"B Snetsinger","year":"2019","unstructured":"Snetsinger B, Ferrone CK, Rauh MJ (2019) Targeted, amplicon-based, next-generation sequencing to detect age-related clonal hematopoiesis. Methods Mol Biol 2045:167\u2013180","journal-title":"Methods Mol Biol"},{"key":"5294_CR81","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1182\/blood.2021011121","volume":"138","author":"T Pincez","year":"2021","unstructured":"Pincez T, Lee SSK, Ilboudo Y et al (2021) Clonal hematopoiesis in sickle cell disease. Blood 138:2148\u20132152","journal-title":"Blood"},{"key":"5294_CR82","doi-asserted-by":"publisher","first-page":"e156060","DOI":"10.1172\/JCI156060","volume":"132","author":"LA Liggett","year":"2022","unstructured":"Liggett LA, Cato LD, Weinstock JS et al (2022) Clonal hematopoiesis in sickle cell disease. J Clin Invest 132:e156060","journal-title":"J Clin Investig"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05294-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05294-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05294-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:20:12Z","timestamp":1744215612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05294-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,3]]},"references-count":82,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["5294"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05294-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,3]]},"assertion":[{"value":"20 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the individual included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors do not have any competing financial interest in relation with the work described.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}}]}}